RxDoctor Payments Data

Melanie Scott, PA

Physician Assistant · Fort Worth, TXNPI 1295257129

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 70 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$244
  • Novo Nordisk$207
  • Biohaven Pharmaceutical Holding Company Ltd.$112
  • Lilly USA, LLC$76
  • AstraZeneca$73
  • Boehringer Ingelheim$67
  • plus $407 from 15 others

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,186 in reported general payments places this provider in the 65th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$26,627
Medicare patients
80
Services billed
796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$58,039
OzempicSemaglutide34$57,115
TrulicityDulaglutide17$39,269
MounjaroTirzepatide25$33,815
Soliqua 100-33Insulin Glargine/Lixisenatide25$29,245
JanuviaSitagliptin Phosphate15$24,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$20,045
EliquisApixaban14$18,470
SynjardyEmpagliflozin/Metformin Hcl11$15,859
Repatha SureclickEvolocumab12$11,668
VascepaIcosapent Ethyl14$5,570
SymbicortBudesonide/Formoterol Fumarate14$4,867
Ibandronate Sodium48$2,750
Atorvastatin Calcium182$1,822
Levothyroxine Sodium179$1,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$67$73,89748 claims
Lilly USA, LLCTrulicity, Mounjaro$76$73,08342 claims
Novo NordiskOzempic$207$57,11534 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$21$29,24525 claims
GSKTrelegy Ellipta$21$20,04515 claims
PfizerEliquis$54$18,47014 claims
AstraZenecaSymbicort$73$4,86714 claims
AbbVieSynthroid$244$1,27913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →